Appendiceal Lesions

  • Ciaran O’NeillEmail author


Appendiceal Lesions: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make the corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular invasion, lymph node involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and TNM8 are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response. A summary is given of the more common non-carcinoma malignancies that are encountered at this site in diagnostic practice.


Appendiceal tumours Neuroendocrine tumours Carcinoid LAMN Pseudomyxoma peritonei TNM8 


  1. Carr NJ, Bibeau F, Bradley R, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopath. 2017;71:847–58.CrossRefGoogle Scholar
  2. Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia. Am J Surg Pathol. 2016;40:14–26.CrossRefGoogle Scholar
  3. Himlin-Lam D, Montgomery EA. The neoplastic appendix: a practical approach. Diagn Histopath. 2011;17:395–403.CrossRefGoogle Scholar
  4. Pai RK, Hartman DJ, Gonzalo DH, et al. Serrated lesions of the appendix frequentlyharbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. Hum Pathol. 2014;45:227–35.CrossRefGoogle Scholar
  5. Pape UF, Niederle B, Costa F, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix. Neuroendocrinology. 2016;103:144–52.CrossRefGoogle Scholar
  6. Rouzbahman M, Chetty R. Mucinous tumours of appendix and ovary: an overview and evaluation of current practice. J Clin Pathol. 2014;67:193–7.CrossRefGoogle Scholar
  7. Stephenson TJ, Cross SS, Chetty R. Standards and datasets for reporting cancers: dataset for neuroendocrine tumours of the gastrointestinal tract including pancreas. Version 3. London: Royal College of Pathologists; 2012. Google Scholar
  8. Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;7:69–76.CrossRefGoogle Scholar
  9. Sugarbaker PH. Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. AnnSurg. 1994;219:109–11.Google Scholar
  10. Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behaviour of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32:1429–43.CrossRefGoogle Scholar
  11. Yantiss RK, et al. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33:248–55.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Cellular and Molecular PathologyAntrim Area HospitalAntrimIreland

Personalised recommendations